Bismuth quadruple therapy (BQT) is an effective treatment for Helicobacter pylori infection. However, frequent dosing schedules of BQT regimen often compromise drug adherence and may affect treatment outcomes. This retrospective study aimed to ...

BQT consists of a PPI, metronidazole, bismuth, and tetracycline, and is typically administered for 7 to 14 days. The Maastricht VI/Florence consensus, newly published in 2022, advises clinicians to prescribe BQT for 14 days unless 10 days of equally effective therapy is available.

Jan 6, 2022 · This study suggested that twice a day BQT is as effective as four times a day therapy for second-line treatment of H. pylori infection. Keywords: Helicobacter pylori; drug administration schedule; treatment outcome.

Maastricht V/Florence guidelines suggest bismuth-based quadruple therapy (BQT), consisting of a proton pump inhibitor (PPI), bismuth subcitrate, metronidazole, and tetracycline, is a therapeutic option for clarithromycin-resistant H. pylori infection.

BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT—containing bismuth, metronidazole and tetracycline—plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%).

Jul 30, 2022 · Current H. pylori treatment guidelines recommend BQT for 10-14 days. This study aims to compare the eradication extents according to 7-day and 14-day BQT treatment for treatment-naïve clarithromycin-resistant confirmed H. pylori infection.

The use of bismuth-containing quadruple therapy (BQT) in Helicobacter pylori eradication has been increasing. Although the recommended treatment length for BQT is 14 days, longer durations may be associated with higher rates of adverse events.

Currently, different treatment regimens are used for H. pylori eradication such as triple and quadruple therapy. Bismuth-containing quadruple therapy (BQT) has shown favorable outcomes. This study compares 10-day and 14-day BQT regimens to evaluate their efficacy, safety, and compliance rates.

Dec 1, 2023 · The use of bismuth-containing quadruple therapy (BQT) in Helicobacter pylori eradication has been increasing. Although the recommended treatment length for BQT is 14 days, longer durations may be associated with higher rates of adverse events.

Mar 2, 2021 · This randomized, open-label trial aimed to compare the efficacy of 10-day bismuth-containing quadruple therapy (BQT) with 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy (STT) as an empirical first-line Helicobacter pylori therapy.